Status:
COMPLETED
Memory Neuroimaging in Children, Adolescents and Young Adults Following Pediatric Cancer
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Cancer Brain
Pediatric Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
Brain tumours are the leading cause of cancer-related death and morbidity in children, adolescents and young adults. The brain is also one of the most sensitive organs to treatments used in pediatric ...
Eligibility Criteria
Inclusion
- FOR ALL PARTICIPANTS
- Affiliation to or beneficiary of a social security scheme
- French mother tongue
- Sufficient visual, auditory (hearing aids permitted), speaking and writing skills for proper performance of neuropsychological tests
- Written informed consent of the adult participant, or of the representatives of parental authority, if applicable
- FOR IRRADIATED PATIENTS
- Patient treated before 18 years old
- Patient considered cured after irradiation of a brain tumour (complete clinical and iconographic response at 5 years after the end of radiotherapy).
- Patient who has received localized brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy (ependymomas, medulloblastomas, malignant germinal tumours)
- Patient who received 54 or 59.4 Gy in a localized part of the posterior fossa or supra-tentorial brain; or patients who received 54 Gy over all or part of the posterior fossa and prophylactic irradiation of the entire brain
- FOR PATIENTS TREATED BY SURGERY AND/OR CHEMOTHERAPY
- Patients resected from a posterior fossa tumour without radiotherapy (i.e., brain tumours whose treatment does not include first-line radiotherapy: low-grade gliomas including pilocytic astrocytomas)
- Patient treated before 18 years old
- Patient considered cured at 5 years after the end of treatment
Exclusion
- FOR ALL PARTICIPANTS
- Individual under legal protection of adults (judicial safeguard, guardianship, curatorship, institutionalized, or under a mandate for future protection)
- Severe ataxia
- Individual who participated in another research study that included treatment within the previous 3 years
- Individual with a contraindication to MRI (i.e. in particular, cardiac pacemaker or defibrillator carriers, implanted equipment activated by an electrical, magnetic or mechanical system, carriers of haemostatic clips on intracerebral aneurysms, carriers of orthopaedic implants, claustrophobic)
- FOR HEALTHY VOLUNTEERS
- Known neurological or psychiatric history
- History of learning disability or neurodevelopmental disorder follow-up
- Patients undergoing psychotropic treatment (methylphenidate, antidepressants, etc.).
Key Trial Info
Start Date :
February 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04324450
Start Date
February 12 2020
End Date
August 19 2021
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ToNIC / UMR1214
Toulouse, France, 31024